Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Timothy Devos, Tatjana Geukens, Alexander Schauwvlieghe, Kevin K Ariën, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniël Desmecht, David Grimaldi, Bart N Lambrecht, Anne Luyten, Piet Maes, Michel Moutschen, Marta Romano, Lucie Seyler, Michel Toungouz Nevessignsky, Katleen Vandenberghe, Johan van Griensven, Geert VerbekeErika Vlieghe, Jean Cyr Yombi, Laurens Liesenborghs, Peter Verhamme, Geert Meyfroidt

Research output: Contribution to journalArticle

27 Downloads (Pure)

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Original languageEnglish
Article number1024
Number of pages1
JournalTrials
Volume21
Issue number1
DOIs
Publication statusPublished - 14 Dec 2020

Fingerprint

Dive into the research topics of 'Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial'. Together they form a unique fingerprint.

Cite this